🚀 Exciting times in digital health! The latest enterprise adoption of AI report reveals some game-changing trends for our industry. 1. Healthcare is leading the AI revolution faster than expected with $500 million in enterprise AI spend in 2024. 2. Ambient scribes like Abridge and Eleos Health are becoming essential in doctors’ offices, automating documentation and freeing up time for patient care. 3. AI is transforming the entire clinical lifecycle: • Triage and intake (e.g., Notable) • Medical coding (e.g., SmarterDx, Codametrix) • Revenue cycle management (e.g., Adonis, Rivet) 5. We’re seeing a shift from augmenting human workflows to more autonomous AI-powered solutions. What does this mean for digital health? • Improved patient care through reduced administrative burdens • More efficient operations and potential cost savings • Data-driven decision making for personalized treatment plans • Potential to address healthcare workforce challenges The future of healthcare is AI-powered, and it’s happening now. #DigitalHealth #AI #HealthcareTech #FutureOfMedicine https://lnkd.in/grj-_bYD
Geno10X Biosciences
Biotechnology Research
Transforming early disease detection through technology
About us
Geno10X Biosciences is a Canadian AI-enabled biotech building the next-generation of rapid disease tests. Our mission is to offer an intelligent, non-invasive, rapid and accurate infectious disease testing platform that is accessible to everyone. We are an experienced team with deep expertise at the intersection of biology, software, technology commercialization, and business development. Our platform is designed to identify those most in need of advanced care, easing the healthcare journey for both patients and providers.
- Website
-
www.geno10x.com
External link for Geno10X Biosciences
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Vancouver
- Type
- Privately Held
- Founded
- 2024
- Specialties
- Medical Device, Digital Health, Diagnostics, Genomics, Software, Biomanufacturing, Immunoassays, and Molecular Biology
Locations
-
Primary
Get directions
Vancouver, CA
Employees at Geno10X Biosciences
Updates
-
Tuberculosis has reclaimed its position as the world’s leading infectious disease killer, surpassing COVID-19 highlighting a critical need for improved diagnostic strategies and challenges in detecting this pathogen. An estimated 10.6 million people fell ill with TB, and 1.3 million died from it. About 3 million TB cases went undiagnosed or unreported in 2022. The World Health Organization (WHO) now recommends molecular tests as the initial diagnostic tool for TB, moving away from traditional microscopy. This change aims to improve early detection rates. New rapid molecular tests can diagnose TB and test for drug resistance simultaneously within hours. This is a significant improvement over traditional culture methods that can take weeks. Some countries have successfully integrated TB screening with COVID-19 testing, leveraging the infrastructure developed for the pandemic to improve TB detection. Ongoing research into new diagnostic tools, including more sensitive point-of-care tests, is essential to further improve early detection rates. https://lnkd.in/gNhXyBg2
Tuberculosis returns as top infectious disease killer, WHO says
reuters.com
-
We are excited to be a part of this program along with some amazing companies that will shape the Canadian biotech landscape.
Please join us in welcoming the companies and mentors participating in our 2025 Investor Readiness Program (IRP)! This exciting six-month program matches 10 BC small- and mid-size enterprises (SMEs) with individual Entrepreneurs-in-Residence (EIRs). Learn more here: https://lnkd.in/gABb_nW7 Participating SMEs: CereCura Nanotherapeutics Curetech E-Health Inc. Geno10X Biosciences GuideStar Medical Devices ImageCyte Revyn Medical Technologies Inc SeraGene Therapeutics Tochtech Technologies Ltd Torus Biomedical Solutions Inc. TruMotion Technologies Ltd. Participating EIRs: Nancy Harrison, Venture Partner, Amplitude Ventures Brenda Irwin, Managing General Partner, Relentless Venture Fund Norma Sebestyen, Life Sciences Executive Lu Han 韩路 PhD, Partner, Lumira Ventures Malcolm Kendall, Co-founder & CEO, Microbiome Insights Inc. Jason Robertson, Co-founder & Managing Partner, Nimbus Synergies Ali Ardakani, Founder & Managing Partner, Novateur Ventures Inc. David Helliwell, Co-founder & Executive Board Chair, Thrive Health Samuel Mercer, Principal, Samuel Mercer Consulting Geof Auchinleck, CEO, Claris Healthcare Inc
-
-
Our CEO Sourabh Banerjee speaks about his experiences leading up to Geno10X, and about our vision to change how early disease diagnosis is done in the future!
Marketing Consultant/Fractional Marketing Director Helping Life Science Brands Grow🌱CEO, FreshLeaf Marketing | 📗Author, Scientist to CEO™ | Speaker | Podcast Host 🎙️
Imagine this: You came from the lab. You didn't have any formal business training. Yet you went on to be part of launching 3 different companies in 3 countries in forward-thinking sectors like machine learning and materials science. That's exactly what happened to Sourabh Banerjee. With a Ph.D. in biochemistry and molecular biology from the The Rockefeller University, he is now CEO of Geno10X Biosciences, an AI-enabled #medicaldevice company specializing in rapid disease detection. In today's episode, Sourabh shares with us: ✅ How he was part of launching 3 different start-ups in 3 countries ✅ Roadblocks he had to navigate in each region's science and business landscape ✅ Advice he'd give to any start-up founder on leadership, vision vs. execution, and the DOSS method ("don't simplify stupid stuff" 😂). 🎙️🎙️🎙️ 👉LISTEN NOW to Episode 4 of the Scientist to CEO #Podcast: https://lnkd.in/g4RWCpFQ Will you help us spread the word? Send this to a fellow science professional in your network or tag them in the comments! — 🎙️#ScientistToCEO is the business growth podcast for companies built by scientists. 🤓 Co-hosted by Jennifer Andrews, M.Sc., MBA & Erica Sosnowski Scientist to CEO™